Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
Use of tumour-responsive T cells as cancer treatment.
Lancet 373, 673-683 (2009)
The stimulation of a tumour-specific T-cell response has several theoretical advantages over other forms of cancer treatment. First, T cells can home in to antigen-expressing tumour deposits no matter where they are located in the body-even in deep tissue beds. Additionally, T cells can continue to proliferate in response to immunogenic proteins expressed in cancer until all the tumour cells are eradicated. Finally, immunological memory can be generated, allowing for eradication of antigen-bearing tumours if they reoccur. We will highlight two direct methods of stimulating tumour-specific T-cell immunity: active immunisation with cancer vaccines and infusion of competent T cells via adoptive T-cell treatment. Preclinical and clinical studies have shown that modulation of the tumour microenvironment to support the immune response is as important as stimulation of the most appropriate effector T cells. The future of T-cell immunity stimulation to treat cancer will need combination approaches focused on both the tumour and the T cell.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
colony-stimulating factor; antigen-presenting cells; donor lymphocyte infusions; low-dose cyclophosphamide; chronic myeloid-leukemia; node-negative melanoma; receptor gene-transfer; in-vivo persistence; antitumor immunity; metastatic melanoma
ISSN (print) / ISBN
0140-6736
e-ISSN
0099-5355
Journal
Lancet, The
Quellenangaben
Volume: 373,
Issue: 9664,
Pages: 673-683
Publisher
Elsevier
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Virology (VIRO)